Cite
HARVARD Citation
Mazza, S. et al. (2022). Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clinical and translational science. 15 (1), pp. 172-181. [Online].